Merck’s Zostavax Shingles Vaccine Approved For Patients Over 60
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA says Merck would need to present more data to pursue use in patients ages 50-59.
You may also be interested in...
Zostavax Gets Nod For Younger Age Group, But Supply Issues Make Sales Boost Unlikely
Merck's ability to capitalize on FDA approval of the shingles vaccine in patients ages 50-59 years is questionable given ongoing supply constraints.
Zostavax Gets Nod For Younger Age Group, But Supply Issues Make Sales Boost Unlikely
Merck's ability to capitalize on FDA approval of the shingles vaccine in patients ages 50-59 years is questionable given ongoing supply constraints.
CDC Working Group Zostavax Recommendation Reflects FDA Labeling
Immunization against herpes zoster should not be broadened nor limited to persons currently excluded from the label, CDC Shingles Working Group recommends June 30.